What Tirzepatide is
Tirzepatide is a dual GIP and GLP-1 receptor agonist with metabolic effects studied in diabetes and chronic weight management contexts.
Tirzepatide is grouped under Fat Loss + GLP-1s / Approved / Clinical on PeptideFactCheck because it is a major comparison point for semaglutide and a key peptide in modern fat-loss science coverage.
The useful starting point is to separate the molecule itself from the internet story around it. The public hook is dual incretin signaling: GLP-1 plus GIP.
Why people keep looking it up
People look at tirzepatide for weight loss and glucose control, often as the stronger comparison to semaglutide.
Tirzepatide activates GIP and GLP-1 receptor pathways that influence appetite and metabolic signaling.
Tirzepatide tends to stay in the conversation because it touches a familiar public theme: gip receptor, glp-1 receptor, and appetite signaling. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Approved products have strong human evidence for labeled uses. Gray-market versions are a different risk category.
Large human clinical programs and official labels support specific approved uses.
Mechanistic work centers on dual incretin receptor activity and metabolic signaling.
Why this page carries the current tier: Official approval and substantial human clinical evidence for labeled contexts.
The current seed trail for Tirzepatide is pulling from 2 regulatory sources, 1 labels source, 1 literature source, and 1 safety source.
Safety, limits, and regulatory context
Risks should be evaluated from current labeling. Unapproved compounded versions raise FDA quality and representation concerns.
FDA-approved tirzepatide products exist for specific indications. FDA has also warned about unapproved GLP-1 products and misleading sameness claims.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Tirzepatide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Tirzepatide is CID 166567236. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 166567236
- Formula
- C225H348N48O68
- Molecular weight
- 4813
- InChIKey
- BTSOGEDATSQOAF-MCNPHUAVSA-N
Matched synonyms include Tirzepatide, 2023788-19-2, Mounjaro (TN), Zepbound (TN), Tirzepatide free base?, Tirzepatide (JAN/USAN), SCHEMBL29871912, WLZ4518.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Tirzepatide returns 225 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Tirzepatide returns 1962 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- Zepbound, ZEPBOUND, Zepbound KwikPen
- Generic names
- TIRZEPATIDE
- Routes
- SUBCUTANEOUS
- Application numbers
- NDA217806
Indications and usage. 1 INDICATIONS AND USAGE ZEPBOUND ® is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. ZEPBOUND is a glucose-depend...
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS Severe Gastrointestinal Adverse Reactions: Use has been associated with gastrointestinal adverse reactions, sometimes severe. ZEPBOUND is not recommended in patients with severe gastroparesis. ( 5.2 ) Acute Kidney Injury Due to Volume Depletion: Monitor renal function in patients reporting adverse reactions that could lead to volume depletion. ( 5.3 ) Acute Gallbladder Disease: Has been re...
Contraindications. 4 CONTRAINDICATIONS ZEPBOUND is contraindicated in patients with: A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions ( 5.1 )] . Known serious hypersensitivity to tirzepatide or any of the excipients in ZEPBOUND. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with tirzepatide [see Warnings and Precautions ( 5.6 ) and Adverse Reacti...
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.